BioCentury
ARTICLE | Clinical News

IMO-3100: Phase IIa data

December 24, 2012 8:00 AM UTC

Top-line data from a double-blind, U.S. Phase IIa trial in 44 patients with moderate to severe plaque psoriasis showed that once-weekly subcutaneous IMO-3100 for 4 weeks with a 4 week follow-up period missed the primary endpoint of reducing median epidermal thickness at week 8 as measured by skin biopsies vs. placebo (6.4% vs. an increase of 7.7%, p-value not disclosed). According to Idera, a known limitation of skin biopsies after 4 weeks of treatment is that psoriatic plaques do not resolve in a uniform fashion and therefore biopsies "may not provide a representative sampling of lesions." However, 48% of patients treated with either dose of IMO-3100 (n=25) achieved improvements in PASI scores of 35-90% from baseline to week 8, while no patients receiving placebo (n=12) achieved PASI improvements in the 35-90% range (p<0.005). Patients received placebo or once-weekly 0.16 and 0.32 mg/kg subcutaneous IMO-3100 for 4 weeks with a 4 week follow-up period. ...